201 related articles for article (PubMed ID: 25685858)
41. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.
Karkera J; Steiner H; Li W; Skradski V; Moser PL; Riethdorf S; Reddy M; Puchalski T; Safer K; Prabhakar U; Pantel K; Qi M; Culig Z
Prostate; 2011 Sep; 71(13):1455-65. PubMed ID: 21321981
[TBL] [Abstract][Full Text] [Related]
42. Castleman's disease with renal infiltration by polyclonal plasma cells.
Frøkjaer Thomsen O; Ladefoged J
Clin Nephrol; 1998 May; 49(5):328-30. PubMed ID: 9617500
[TBL] [Abstract][Full Text] [Related]
43. Siltuximab: first global approval.
Markham A; Patel T
Drugs; 2014 Jul; 74(10):1147-52. PubMed ID: 24958337
[TBL] [Abstract][Full Text] [Related]
44. Angiofollicular lymph node hyperplasia resembling a spinal nerve sheath tumor: a rare case of Castleman's disease.
Stevens EA; Strowd RE; Mott RT; Oaks TE; Wilson JA
Spine J; 2009 Sep; 9(9):e18-22. PubMed ID: 19482516
[TBL] [Abstract][Full Text] [Related]
45. [Retroperitoneal Castleman's disease. A report of two cases and analysis of the literature].
Ridolfini MP; Rotondi F; Gourgiotis S; Alfieri S; Di Miceli D; Larocca LM; Doglietto GB
Chir Ital; 2007; 59(1):53-61. PubMed ID: 17361931
[TBL] [Abstract][Full Text] [Related]
46. Clonal rearrangement for immunoglobulin and T-cell receptor genes in systemic Castleman's disease. Association with Epstein-Barr virus.
Hanson CA; Frizzera G; Patton DF; Peterson BA; McClain KL; Gajl-Peczalska KJ; Kersey JH
Am J Pathol; 1988 Apr; 131(1):84-91. PubMed ID: 2833104
[TBL] [Abstract][Full Text] [Related]
47. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.
Deisseroth A; Ko CW; Nie L; Zirkelbach JF; Zhao L; Bullock J; Mehrotra N; Del Valle P; Saber H; Sheth C; Gehrke B; Justice R; Farrell A; Pazdur R
Clin Cancer Res; 2015 Mar; 21(5):950-4. PubMed ID: 25601959
[TBL] [Abstract][Full Text] [Related]
48. Concurrence of localized Castleman's disease and peripheral small B-Lymphocytic lymphoma within the same lymph node.
Orcioni GF; Mambelli V; Ascani S; Sabattini E; Piccioli M; Pieri F; Falini B; Pileri SA
Gen Diagn Pathol; 1998 Apr; 143(5-6):327-30. PubMed ID: 9653916
[TBL] [Abstract][Full Text] [Related]
49. Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2.
Konishi Y; Takahashi S; Nishi K; Sakamaki T; Mitani S; Kaneko H; Mizutani C; Ukyo N; Hirata H; Tsudo M
Tohoku J Exp Med; 2015 Aug; 236(4):289-95. PubMed ID: 26250536
[TBL] [Abstract][Full Text] [Related]
50. Idiopathic multicentric Castleman's disease. A clinicopathologic and immunohistochemical study of five cases.
Kojima M; Nakamura S; Nishikawa M; Itoh H; Miyawaki S; Masawa N
Pathol Res Pract; 2005; 201(4):325-32. PubMed ID: 15991840
[TBL] [Abstract][Full Text] [Related]
51. Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
van Rhee F; Rothman M; Ho KF; Fleming S; Wong RS; Fosså A; Dispenzieri A; Cavet J; Munshi N; Vermeulen J; Casper C
Patient; 2015 Apr; 8(2):207-16. PubMed ID: 25736164
[TBL] [Abstract][Full Text] [Related]
52. Hyaline vascular type of unicentric Castleman's disease with proliferation of glomerular endothelial cells.
Wakabayashi K; Asanuma K; Takeda Y; Arakawa A; Osawa I; Horikoshi S; Yao T; Tomino Y
Clin Nephrol; 2014 Jun; 81(6):445-50. PubMed ID: 23211339
[TBL] [Abstract][Full Text] [Related]
53. Multicentric Castleman's disease complicated by tumor lysis syndrome.
Lee KD; Lee KW; Choi IS; Yoon SS; Park S; Kim BK; Kim NK
Ann Hematol; 2004 Nov; 83(11):722-5. PubMed ID: 15316754
[TBL] [Abstract][Full Text] [Related]
54. Involvement of human interleukin-6 in systemic manifestations of human herpesvirus type 8-associated multicentric Castleman's disease.
Foussat A; Fior R; Girard T; Boue F; Wijdenes J; Galanaud P; Emilie D
AIDS; 1999 Jan; 13(1):150-2. PubMed ID: 10207568
[No Abstract] [Full Text] [Related]
55. Complete remission with anti-CD20 therapy for unicentric, non-HIV-associated, hyaline-vascular type, Castleman's disease.
Estephan FF; Elghetany MT; Berry M; Jones DV
Cancer Invest; 2005; 23(2):191. PubMed ID: 15813512
[No Abstract] [Full Text] [Related]
56. Hyaline vascular Castleman's disease: a case report and brief review of the literature.
van den Berge M; Pauwels P; Jakimowicz JJ; Creemers GJ
Neth J Med; 2002 Dec; 60(11):444-7. PubMed ID: 12685494
[TBL] [Abstract][Full Text] [Related]
57. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody.
Gholam D; Vantelon JM; Al-Jijakli A; Bourhis JH
Ann Hematol; 2003 Dec; 82(12):766-8. PubMed ID: 12898190
[TBL] [Abstract][Full Text] [Related]
58. Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease.
Vernon M; Robinson D; Trundell D; Ishak J; Jen MH; Brazier J
Curr Med Res Opin; 2016 Jul; 32(7):1193-200. PubMed ID: 26972925
[TBL] [Abstract][Full Text] [Related]
59. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities.
Kampan NC; Xiang SD; McNally OM; Stephens AN; Quinn MA; Plebanski M
Curr Med Chem; 2018; 25(36):4785-4806. PubMed ID: 28707587
[TBL] [Abstract][Full Text] [Related]
60. Castleman's disease and arterial thrombosis: result of excessively elevated interleukin-6 plasma level?
Schumacher A; Jacomella V; Stüssi G; Amann-Vesti B; Corti N; Husmann M
Vasa; 2012 Mar; 41(2):145-8. PubMed ID: 22403134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
